Artelo Biosciences, Inc. (NASDAQ:ARTL) Receives Average Rating of “Hold” from Brokerages

Shares of Artelo Biosciences, Inc. (NASDAQ:ARTL) have earned an average rating of “Hold” from the five analysts that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $24.00.

Several analysts have commented on ARTL shares. Wall Street Zen cut shares of Artelo Biosciences to a “strong sell” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (d-)” rating on shares of Artelo Biosciences in a report on Wednesday, October 8th. D Boral Capital cut Artelo Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, September 8th. Finally, D. Boral Capital reiterated a “hold” rating on shares of Artelo Biosciences in a research report on Monday, September 8th.

Artelo Biosciences Stock Down 2.0%

ARTL stock opened at $3.38 on Thursday. The stock has a market capitalization of $2.37 million, a price-to-earnings ratio of -0.18 and a beta of 1.41. Artelo Biosciences has a twelve month low of $3.15 and a twelve month high of $28.60. The firm’s fifty day simple moving average is $6.17 and its two-hundred day simple moving average is $7.81.

Artelo Biosciences (NASDAQ:ARTL) last released its earnings results on Wednesday, August 13th. The company reported ($5.61) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($5.48). As a group, equities research analysts expect that Artelo Biosciences will post -2.62 EPS for the current year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.